Table 3.
Univariate and multivariate analyses of laboratory and clinical indicators with BCNACT pathologic complete response on external validation patients.
| Indicators | Total | pCR | Univariate analysis | Multivariate analysis (Hosmer–Lemeshow test, P = 0.853) | ||
|---|---|---|---|---|---|---|
| No | Yes | p-value | RR (95% CI) | p-value | ||
| 135 | 119 | 16 | ||||
| Age, year | 0.517 | 0.226 | ||||
| <50 | 64 | 56 | 8 | 1 (reference) | ||
| ≥50 | 71 | 63 | 8 | 0.277 (0.035–2.207) | ||
| BMI, kg/m2 | 0.435 | 0.259 | ||||
| <25 | 83 | 73 | 10 | 1 (reference) | ||
| 25 ≤ BMI <30 | 44 | 38 | 6 | 3.388*106 (0.000−~) | 0.999 | |
| ≥30 | 8 | 8 | 0 | 1.615*107 (0.000−~) | 0.999 | |
| Menopausal status | 0.450 | 0.092 | ||||
| Premenopausal | 78 | 68 | 10 | 1 (reference) | ||
| Postmenopausal | 57 | 51 | 6 | 6.419 (0.737–55.916) | ||
| WC, cm | 0.048 | 0.998 | ||||
| ≤93.665 | 113 | 97 | 16 | 1 (reference) | ||
| >93.665 | 22 | 22 | 0 | 3.883*108 (0.000−~) | ||
| FBG, mmol/L | 0.012 | 0.023 | ||||
| ≤5.415 | 91 | 76 | 15 | 1 (reference) | ||
| >5.415 | 44 | 43 | 1 | 79.074 (1.809–3456.590) | ||
| Blood pressure | ||||||
| SBP, mmHg | 0.430 | 0.060 | ||||
| ≤137.5(没变) | 99 | 88 | 11 | 1 (reference) | ||
| >137.5 | 36 | 31 | 5 | 0.038 (0.002–1.093) | ||
| DBP, mmHg | 0.262 | 0.603 | ||||
| ≤83.5 | 96 | 83 | 13 | 1 (reference) | ||
| >83.5 | 39 | 36 | 3 | 1.788(0.200–15.958) | ||
| Lipid profile | ||||||
| TG, mmol/L | 0.240 | 0.666 | ||||
| ≤1.525 | 95 | 82 | 13 | 1 (reference) | ||
| >1.525 | 40 | 37 | 3 | 1.528 (0.223–10.452) | ||
| HDL-C, mmol/L | 0.337 | 0.997 | ||||
| ≤1.465 | 27 | 25 | 2 | 1 (reference) | ||
| >1.465 | 108 | 94 | 14 | 0.996 (0.111–8.955) | ||
| TC, mmol/L | 0.195 | |||||
| ≤4.720 | 75 | 64 | 11 | |||
| >4.720 | 60 | 55 | 5 | |||
| LDL-C, mmol/L | 0.467 | |||||
| ≤3.225 | 87 | 76 | 11 | |||
| >3.225 | 48 | 43 | 5 | |||
| UA, μmol/L | 0.295 | 0.081 | ||||
| ≤221.5 | 39 | 33 | 6 | 1 (reference) | ||
| >221.5 | 96 | 86 | 10 | 4.788 (0.827–27.734) | ||
| Cr, μmol/L | 0.567 | |||||
| ≤53.9 | 28 | 25 | 3 | |||
| >53.9 | 107 | 94 | 13 | |||
| LDH, U/L | 0.142 | |||||
| ≤162 | 36 | 34 | 2 | |||
| >162 | 99 | 85 | 14 | |||
| Inflammation | ||||||
| NLR | 0.240 | |||||
| ≤1.925 | 40 | 37 | 3 | |||
| >1.925 | 95 | 82 | 13 | |||
| LMR | 0.309 | |||||
| ≤6.585 | 98 | 85 | 13 | |||
| >6.585 | 37 | 34 | 3 | |||
| PLR | 0.415 | |||||
| ≤114.085 | 33 | 30 | 3 | |||
| >114.085 | 102 | 89 | 13 | |||
| Tumor size | 0.346 | |||||
| T ≤ 2 cm | 25 | 22 | 3 | |||
| 2 cm < T≤ 5 cm | 100 | 87 | 13 | |||
| T > 5 cm | 10 | 10 | 0 | |||
| Lymph node | 0.102 | |||||
| Negative | 52 | 43 | 9 | |||
| Positive | 83 | 76 | 7 | |||
| Clinical stage | 0.076 | |||||
| I | 10 | 8 | 2 | |||
| IIA | 57 | 49 | 8 | |||
| IIB | 55 | 49 | 6 | |||
| III | 13 | 13 | 0 | |||
| Pathogenic type | 1.000 | |||||
| Invasive carcinoma | 125 | 109 | 16 | |||
| Invasive carcinoma with ductal carcinoma |
6 | 6 | 0 | |||
| Others | 0 | 8 | 8 | |||
| Molecular subtype | <0.001 | |||||
| HER2+/HR+ | 27 | 23 | 4 | |||
| HER2+/HR– | 14 | 9 | 5 | |||
| Luminal | 73 | 71 | 2 | |||
| TNBC | 21 | 16 | 5 | |||
| ER | 0.003 | 0.552 | ||||
| Negative | 39 | 29 | 10 | 1 (reference) | ||
| Positive | 96 | 90 | 6 | 1.764 (0.272–11.413) | ||
| PR | 0.002 | 0.093 | ||||
| Negative | 53 | 41 | 12 | 1 (reference) | ||
| Positive | 82 | 78 | 4 | 7.208 (0.719–72.297) | ||
| HER2 | 0.020 | 0.023 | ||||
| Negative | 94 | 87 | 7 | 1 (reference) | ||
| Positive | 41 | 32 | 9 | 0.157 (0.063–0.519) | ||
| Ki-67 | 0.219 | |||||
| Negative | 14 | 11 | 3 | |||
| Positive | 121 | 108 | 13 | |||
| TNBC | 0.077 | |||||
| Yes | 21 | 16 | 5 | |||
| No | 114 | 103 | 11 | |||
| NACT regimen | 0.176 | |||||
| Non-taxane based | 34 | 32 | 2 | |||
| Taxane based | 101 | 87 | 14 | |||
| MetS | 0.011 | 0.046 | ||||
| No | 80 | 66 | 14 | 1 (reference) | ||
| Yes | 55 | 53 | 2 | 9.416 (1.038–85.443) | ||
pCR, pathologic complete response; RR, risk ratio; CI, confidence interval; BMI, body mass index; WC, waist circumference; FBG, fasting blood glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; TC, total cholesterol; LDL-C; low-density lipoprotein cholesterol; UA, uric acid; Cr, creatinine; LDH, lactate dehydrogenase; NLR, neutrophil-lymphocyte ratio; LMR, lymphocyte-monocyte ratio; PLR, platelet-lymphocyte ratio; HER2, human epidermal growth factor 2; HR, hormone receptor; TNBC, triple negative breast cancer; ER, estrogen receptor; PR, progesterone receptor; NACT, neoadjuvant chemotherapy. Bold means p-value < 0.05. * means multiplication.